首页> 美国卫生研究院文献>JIMD Reports >Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops
【2h】

Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops

机译:贮存条件对眼科复合半胱胺滴眼液稳定性的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cystinosis is a hereditary genetic disease that results in the accumulation of cystine crystals in the lysosomes, leading to many clinical manifestations. One of these manifestations is the formation of corneal cystine crystals, which can cause serious ocular complications. The only available drug to treat cystinosis is cysteamine, which breaks cystine and depletes its accumulation in the lysosomes. However, the oral form of cysteamine is not effective in treating corneal manifestations. Thus, ophthalmic solutions of cysteamine are applied. Because the commercial cysteamine eye drops are not available in most countries, hospital pharmacies are responsible for preparing “homemade” drops usually without a control of stability of cysteamine in different storage conditions. Hence, we aimed in this study to investigate the effect of different storage conditions on the stability of a cysteamine ophthalmic compounded solution. Cysteamine ophthalmic solution was prepared in the hospital pharmacy and sterilized using a candle filter. The preparations are then stored either in the freezer at −20°C or in the refrigerator at +4°C for up to 52 weeks. The amount of cysteamine hydrochloride in the preparation at different time points was determined using capillary electrophoresis (CE). Storage of the cysteamine ophthalmic preparations at +4° resulted in significant loss of free cysteamine at all time points, from 1 to 52 weeks of storage, when compared with storage in the freezer (−20°C). We demonstrate that cysteamine 0.5% compounded eye drops are easily oxidized within the first week after storage at +4°C, rendering the preparation less effective. Storage at −20°C is recommended to prevent this process.
机译:胱氨酸病是一种遗传性遗传疾病,导致溶酶体中胱氨酸晶体的积累,从而导致许多临床表现。这些表现之一是角膜胱氨酸晶体的形成,其可引起严重的眼部并发症。治疗胱氨酸病的唯一可用药物是半胱胺,其可破坏胱氨酸并消耗其在溶酶体内的积累。然而,半胱胺的口服形式在治疗角膜表现方面无效。因此,使用了半胱胺的眼药水。由于在大多数国家/地区都无法购买到商业上的半胱胺滴眼液,因此医院药房负责制备“自制”滴眼液,通常在不同存储条件下都无法控制半胱胺的稳定性。因此,我们在这项研究中旨在研究不同储存条件对半胱胺眼科复合溶液稳定性的影响。半胱胺滴眼液在医院药房中制备,并使用蜡烛过滤器灭菌。然后将制剂在-20°C的冰箱中或+ 4°C的冰箱中保存长达52周。使用毛细管电泳(CE)测定不同时间点制剂中盐酸半胱胺的量。与在冰箱中(-20°C)相比,将半胱胺眼用制剂在+ 4°的条件下储存会导致在所有时间点(从1到52周)的游离半胱胺大量损失。我们证明,在+ 4°C下储存后的第一周内,0.5%的半胱胺复合滴眼液很容易被氧化,使制剂的效力降低。建议在-20°C下存储以防止此过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号